Imaging Markers Tracking Lewy Body Disease Over Time
Studies brain scans over time in people with Lewy body disease using a tracer.
Plain-language title generated from the registry record
Registry title: Longitudinal Imaging Biomarkers of Disease Progression in DLB
Key facts
- Where
- Jacksonville and Rochester, United StatesSee the 2 sites
- Phase
- Phase 4
Where in United States
- Mayo ClinicJacksonville, United StatesNo longer taking part
- Mayo ClinicRochester, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kejal Kantarci
- Trial code
- NCT03582488
- Record updated
- 19 March 2026
- Original description
The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.Read full original descriptionShow less
Longitudinal Imaging Biomarkers of Disease Progression in DLB
The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.
Inclusion: Diagnosis of probable DLB, at least 18 years of age, reliable informant who personally speaks with or sees the participant at least weekly, sufficiently fluent in English, must be willing and able to consent to the protocol and undergo up to 6 visits over 5 years, willing and able to undergo neuropsychological testing and no contraindication to MRI imaging.
Exclusion: Presence of another neurologic disorder which could impact findings, such as multiple sclerosis, brain tumors, etc., unwilling to return for follow-up yearly and undergo neuropsychological testing and MR imaging, if undergoing Tau imaging cannot have QT Prolongation, do not have a reliable informant.